RegWardenFDA facility compliance records
Recall

Class II — Intrinsic Therapeutics, Inc.

Recalling firmIntrinsic Therapeutics Inc.
Registered facilityIntrinsic Therapeutics, Inc. (the firm's only registered facility)
ClassificationClass II
StatusTerminated
ReasonThe catalog ( REF ) number on the peelable inner labels (patient sticker) that is on the inner container (box) is incorrect. It states BAR-A8-10MM instead of BAR-A8-8MM.
ProductBarricaid Annual Closure Device (ACD) BAR-A8-8MM - Product Usage: The Barricaid® ACD is indicated for reducing the incidence of reherniation, and reoperation in skeletally mature patients with radiculopathy (with or without back pain) attributed to a posterior or posterolateral herniation, and confirmed by history, physical examination and imaging studies which demonstrate neural compression using MRI to treat a large annular defect (between 4-6 mm tall and between 6-10 mm wide) following a primary discectomy procedure (excision of herniated intervertebral disc) at a single level between L4 an…
Quantity110 units
DistributionUS Nationwide distribution.
Initiated2020-07-24
Classified2020-08-13
Terminated2020-09-16
Recall numberZ-2798-2020
InitiationVoluntary: Firm initiated

Source: U.S. FDA via openFDA (opens in a new tab) (device registration & enforcement). Data as of 2026-10-06. Verify this recall record at FDA → (opens in a new tab)

Cite this record

RegWarden. “Class II recall — Intrinsic Therapeutics, Inc. (Z-2798-2020).” Compiled from U.S. FDA public records (openFDA; FDA Data Dashboard). Data as of 2026-10-06. https://regwarden.com/recall/86121/

Not open yet

Alerts for Intrinsic Therapeutics Inc.

Watchlist alerts will email you when FDA publishes a new recall, inspection classification, or warning letter for a facility you follow. They aren't open to the public yet — leave your email and we'll tell you when they are.

Planned

Want a one-page facility brief?

A single-page summary of this facility's registration and recall history for diligence. Not selling it yet — register interest and we'll follow up.